Case Report

Manic episode after Amisulpride monotherapy: an unexpected presentation.

Priyanka Jog¹
Devavrat Harshe²
Deoraj Sinha³
Ravindra Kamath⁴

¹Resident Doctor
²Senior Resident Doctor
³Assistant Professor
⁴Professor and Head
Department of Psychiatry, Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai.
E-mail – devavrat.harshe@gmail.com

ABSTRACT

Amisulpride is an unique atypical antipsychotic with a mechanism of action on dopamine receptors that is effective in positive as well as negative symptoms. There are some reports of Amisulpride being useful in treatment resistant depression as well. Mania has been reported as a result of Amisulpride so far in only two cases. We present here an case with psychotic features that developed mania induced by Amisulpride at a dose of 150mg.

Key words: Amisulpride, mania, drug induced mania.

INTRODUCTION

Among all atypical antipsychotics, Amisulpride has few unique properties. It has minimal affinity for 5-HT₂ receptors. It also has affinity for D₂ and D₃ receptors. Perhaps these properties of Amisulpride have resulted in it being described as an unusual atypical antipsychotic [1].

Like all psychopharmacological agents, Amisulpride is associated with certain adverse effects. Common adverse effects reported with Amisulpride are extrapyramidal side effects (dystonia, tardive dyskinesia), drowsiness, agitation, anxiety, hyperprolactinemia, galactorrhoea, gynaecomastia, and amenorrhoea. Rare effects include NMS, reduction in seizure threshold, hypotension and QT prolongation [2-3].
Apart from all these, manic episodes after initiation of amisulpride in management of schizophrenia have been reported. We could find only 2 reports [4-5] in the literature and hence, decided to present this case.

CASE REPORT

An 18-year-old male presented with aggressive abusive behavior, social withdrawal, disturbed sleep and preoccupation with thoughts about his appearance since 2 years prior to presentation. The patient was admitted in the ward and was investigated with routine investigations (complete blood counts, liver and renal function tests). It was reported by the caregivers that a year prior, the patient had a similar episode and was treated with Amisulpride (dose unavailable) on which the patient and relatives reported approximately 75% improvement. Considering this history, Amisulpride was restarted at a dose of 50 mg. The dose of Amisulpride was titrated up to 150 mg over next 7 days by 50 mg increments every 3 days. Within 48 hours after the dose titration to 150 mg, the patient developed a decreased need for sleep, increased psychomotor activity, distractibility, disinhibition, inappropriate laughter, overfamiliarity, jocularity, sudden anger outbursts and irritability. Mental status examination showed ill sustained attention, rapidly established rapport, elated mood, flight of ideas, clang association, pseudo-philosophical ideas. Severity of symptoms on Young Mania Rating Scale (YMRS) [6] was 22. Amisulpride was stopped and the patient was started on Haloperidol 5 mg and Trihexyphenylidyl 2 mg orally per day. The dose of Haloperidol as titrated to 10 mg respectively over next 4 days. YMRS score dropped to 17 after day 4, 10 after 7 days and 0 after 2 weeks of treatment. The patient showed full symptomatic recovery for all manic symptoms over the next 7 days with a rapid improvement in all psychotic symptoms as well.

DISCUSSION

Drug induced mania or “poop out” phenomenon is a big concern in clinical practice. Sudden change in patient’s mood and behavior ranging from hyperthymia to hypomania to a full blown manic episode, especially after the treatment can cause anxiety, apprehension, fear and distrust towards the treatment in the mind of caregivers. It also leads to an increase in caregiver burden due to increase in inpatient stay and an increase in treatment cost incurred due to switching the culprit drug with another. Common drugs implicated in drug-induced mania or switch, are usually antidepressants in all groups with a higher risk in tricyclic antidepressants and selective serotonin reuptake inhibitors with the least risk being with Bupropion. It is ironic that although atypical antipsychotics are often used for the treatment of manic episodes, literature exists to show a manic switch with Olanzapine, Risperidone, Clozapine, Quetiapine, Ziprasidone, Aripiprazole, Amisulpride, Zotepine and Paliperidone [3] totaling to 28 cases being reported. It is worth mentioning that we were unable to find case reports mentioning a manic switch/episode after first generation antipsychotics.

To the best of our knowledge, only 2 case reports of Amisulpride induced mania exist in the literature. The first case report [4] described a manic episode in a patient diagnosed as schizophrenia with 400 mg Amisulpride and 20 mg Citalopram who developed mania after 90 days of Amisulpride treatment. However, the second case report [5] presents the case of a patient diagnosed with schizophrenia, treated with 4 mg Risperidone for 1 and a half-year, augmented with Amisulpride 100 mg and the patient presented with a manic episode after 10 days of treatment.
It has been demonstrated that, the risk of antidepressant induced switch is more in patients with bipolar I disorder, lower age at onset, hyperthymic temperament and those on lithium [7]. However, no such risk factors have been identified for antipsychotic induced switch. Since almost all the cases of antipsychotic induced switch (AIS) are after atypical antipsychotic regimen, the cause can be hypothesized to be the action on serotonergic receptors. Further research is vital in this domain, to evaluate the incidence of AIS, as well as the risk factors associated with it. This is particularly important for Amisulpride, Quetiapine and Aripiprazole, which are used in treatment of depressive disorders and a switch after using them cause considerable distress and burden to the patient, the caregiver and the treating doctor as well.

REFERENCES


Acknowledgements – Nil
Conflict of Interest – Nil
Funding - Nil